A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response or relapsed after first line steroid treatment (VAYHIT2)

  • Bennett, Ashwini (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

ERM Reference Number: HREC/90716/MonH-2023-354957(v1)
Monash Health Local Reference: RES-23-0000-100A
StatusActive
Effective start/end date6/09/23 → 5/09/28

Clinical Trial Phase

  • Phase III (a & b)